Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have received an average recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $16.50.
A number of brokerages have issued reports on DVAX. BidaskClub upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Friday, August 16th. Finally, Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Dynavax Technologies by 95.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,402 shares during the period. Bank of Montreal Can increased its stake in shares of Dynavax Technologies by 148.4% during the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 4,445 shares during the last quarter. Wedbush Securities Inc. purchased a new position in shares of Dynavax Technologies during the 2nd quarter worth about $42,000. Ingalls & Snyder LLC purchased a new position in shares of Dynavax Technologies during the 3rd quarter worth about $52,000. Finally, M&T Bank Corp boosted its position in shares of Dynavax Technologies by 29.5% in the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 3,116 shares during the last quarter. Institutional investors own 82.36% of the company’s stock.
Shares of Dynavax Technologies stock traded up $0.14 on Thursday, hitting $5.57. The company’s stock had a trading volume of 85,338 shares, compared to its average volume of 1,000,796. The company has a market capitalization of $473.84 million, a price-to-earnings ratio of -2.17 and a beta of 0.56. Dynavax Technologies has a 1 year low of $2.60 and a 1 year high of $12.42. The company has a debt-to-equity ratio of 5.48, a quick ratio of 4.09 and a current ratio of 4.94. The firm has a fifty day moving average price of $5.20 and a 200-day moving average price of $4.39.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). The business had revenue of $10.58 million for the quarter, compared to analysts’ expectations of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The business’s revenue for the quarter was up 624.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.65) EPS. As a group, analysts forecast that Dynavax Technologies will post -2.04 EPS for the current year.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Read More: How do investors use RSI to grade stocks?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.